It is just, as you said, it is an exciting time in the world of chronic GvHD. For several reasons, one is that we now have three drugs that are approved for chronic GvHD, which is just giving us more options to treat the patients. But I still think that the right answer when people ask me what drug to choose or what’s the right way to treat the patients with chronic GvHD the right answer is still put these patients on well-designed clinical trials...
It is just, as you said, it is an exciting time in the world of chronic GvHD. For several reasons, one is that we now have three drugs that are approved for chronic GvHD, which is just giving us more options to treat the patients. But I still think that the right answer when people ask me what drug to choose or what’s the right way to treat the patients with chronic GvHD the right answer is still put these patients on well-designed clinical trials. I think that we still treat these patients kind of empirically. We don’t quite know, or sometimes we think we know, but we don’t really, which drug is best for which kind of patient and which drug to try first. So I think that we will see down the road more studies either combining these drugs in certain way, or testing them next to each other. So I think that the time to come will have more interesting studies for chronic GvHD. But one important thing that there has been a lot of talk in the chronic GvHD consortium was also testing drugs earlier on for newly diagnosed GvHD in a steroid-sparing fashion. So where you could test these drugs without really using high doses of steroids upfront. And biomarkers, I think biomarkers that there is a lot we know about biomarkers in acute, but there has been a lot of work about current research in the use of biomarkers for chronic GvHD and testing different different biomarkers.
